公司资料
ARS Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- SPRY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
6.24 USD (+10.44%)
收盘价
最后更新: 2026年8月17日
884M USD
市值
股价为何变动
As of Aug 17, 2026, SPRY closed up 10.4% at $6.24. No new same-company headline was identified in the current news window.
公司概览
Needle-Free Epinephrine Company
ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union.
Neffy Commercialization
The company is building U.S. sales, payer access, prescription-refill programs, and pharmacy affordability support while expanding internationally through regional partners. Health Canada has approved neffy, with ALK responsible for Canadian commercialization.
Patient-Centered Delivery Strategy
The nasal formulation is intended to remove barriers associated with injectable epinephrine, including needle anxiety, complex administration, and hesitation during emergencies. ARS is building its commercial strategy around portability, ease of use, and broader willingness to carry treatment.
Intranasal Epinephrine Platform Expansion
Beyond emergency allergy treatment, ARS is evaluating intranasal epinephrine for acute flares of chronic spontaneous urticaria and has advanced the program into a Phase 2b study.
International Partnership Model
ARS uses regional partners to extend neffy beyond its direct U.S. commercial organization. These partners assume responsibility for local regulatory, distribution, and launch activities while broadening the geographic value of the product.
未来催化剂
- Interim Phase 2b data for intranasal epinephrine in chronic spontaneous urticaria in the first quarter of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。